Periodic Reporting for period 2 - ID-PROSTATE (Integrated Diagnostics for Prostate Cancer)
Période du rapport: 2021-07-01 au 2022-06-30
Prostate cancer is the most common type of cancer in men and their second leading cause of death; however, it is highly treatable in the early stages. Recent studies and clinical trials have demonstrated the efficiency of prostate MRI in early diagnosis, with 5 times less missed cancer cases and 25 % fewer biopsies. Care standards now recommend MRI prior to every biopsy, leading to an increased demand for prostate MRI scans. Conventional radiology reading capacity cannot keep pace with the demand. Quantib BV (Netherlands) developed an AI-enhanced integrated diagnostic solution for the detection of potential tumors and workflow optimization involving urologists, radiologists and pathologists. The current EU-funded ID-PROSTATE project allows further improvement and acceleration focusing on product commercialization.
An initial version of Quantib Prostate was completed and certified for clinical use in both the United States (FDA clearance) as well as within the EU (CE-certification). This initial version is in use across a network of sites leading to workflow / UX improvements being released rapidly. In addition this initial version has provided critical insight into the needs for the expanded version featuring additional AI-components which has now also been submitted for review to the FDA.
We expect the expanded version will deliver the ability for clinicians to report on prostate MR at speed beyond the current state-of-the-art. This will impact the adoption and high-quality and cost-effective use of MRI in early diagnosis of prostate cancer and will thus impact men across Europe and the United States.